CRL
Charles River Laboratories Inte
Diagnostics & Research · Healthcare · United States
376.10
close · 2026-10-29
value
59
cheaper than peers59
quality
14
stronger fundamentals14
ranked against
Diagnostics & Research
value
quality
31 peers
Value inputs
| measure | company | vs peers |
| EV to EBITDA | 18.33× | 74 |
| price to sales | 3.22× | 60 |
| price to book | 6.32× | 50 |
| forward P/E | 29.51× | 48 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 15.1% | 65 |
| return on equity | -7.5% | 36 |
| debt to equity | 105.0% | 19 |
| revenue growth | -2.7% | 11 |
4 of 4 measures available
Facts
| market cap | $18B |
| free cash flow | $468.9M |
| employees | 18,300 |
| first trade | 2000-06-23 |
| next earnings | 2026-11-04 |
| fundamentals updated | 2026-08-07 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -2.91 | 0.20 | 9.22 | 9.48 |
| free cash flow | $518.5M | $501.6M | $365.4M | $294.9M |
| net income | -$144.3M | $10.3M | $474.6M | $486.2M |
| revenue | $4.02B | $4.05B | $4.13B | $3.98B |
| unusual items | -$376.0M | -$215.0M | $0 | $0 |